Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 1998

View Archived Issues

Protein Design Labs and Genentech enter agreement for antibody patents

Gatifloxacin highlighted at ICAAC as an effective new treatment for pneumonia

FDA approves Serevent Diskus for maintenance treatment of pediatric asthma

Spotlight on antifungal agents for treating aspergillosis

New treatment for CMV retinitis in the pipeline at Roche

Development status updated for 3M's imiquimod analogue R-848

Patent issued for Neoprobe's RIGS/ACT anticancer technology

Abbott initiates phase II trials with ABT-606

Spotlight on drug therapy for hepatitis

Cell Genesys receives milestone payment from HMR for GA-EPO agreement

University of Pittsburgh recruits patients for Somnoplasty clinical trial

Data suggest Ossigel significantly accelerates fracture healing

Synthesis and activity of new antifungal agents reported by Nihon Nohyaku

Wakamoto discovers natural substances for Alzheimer's disease

Rovi introduces LMW heparin in Spain

New agents for cytokine- and/or CAM-mediated disorders disclosed by Pfizer

Chalcone derivatives show potential in the treatment of leishmaniasis

Centocor launches new treatment for Crohn's disease

Leflunomide market introduction announced

rPAF-AH shows neuroprotective activity in hippocampal neurons

Emory University issued U.S. patent for FTC compound

Alza to acquire Sequus

FDA committee recommends approval of Epivir-HBV

Long-acting fluorine-containing prostaglandins for ocular diseases

ADIR presents two new series of ellipticine derivatives with improved profiles

Nonpeptide BK antagonist effective in guinea pig models of allergy

Melatonin neuroprotective in a mouse TBI model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...